Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

From first conversation right through to negotiations I would summarise your involvement in the process as (i) highly professional (ii) consultative and (iii) thoroughly supportive.
Ben , 2013

Amgen reports positive data from kidney disease drug trial

22 July 2014 11:06 in Pharmaceutical Company Product News

Amgen reports positive data from kidney disease drug trialAmgen has announced positive data from a phase III study evaluating its drug AMG 416 in the treatment of conditions relating to chronic kidney disease.

The drug was able to meet all of its primary and secondary endpoints in the new study, which assessed the compound in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who were receiving haemodialysis.

Amgen's therapy was associated with a significant drop in parathyroid hormone levels when administered three times per week by intravenous injection.

Data from a second placebo-controlled study will be made available later this year, while a head-to-head study evaluating AMG 416 compared to cinacalcet will be published in 2015.

Dr Sean Harper, executive vice president of research and development at Amgen, said: "Secondary hyperparathyroidism can be a challenging disease to manage and control. There is an important role for an effective calcimimetic that can be administered intravenously with haemodialysis to help treat this disease."

This comes after the company reported positive data from a phase II trial of its psoriatic arthritis therapy brodalumab last month. ADNFCR-8000103-ID-801736791-ADNFCR

Other news stories from 22/07/2014

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd